Champions Oncology Earnings Call Transcripts
Fiscal Year 2026
-
Record annual revenue and positive Adjusted EBITDA were achieved, driven by strong core services growth and operational improvements. Data revenue declined due to a non-recurring large transaction, but the customer base expanded and margins improved. Investments position the company for future growth.
-
Record core study revenue and positive adjusted EBITDA offset a year-over-year revenue decline due to the absence of data revenue. Early traction in the data business and continued investment in growth initiatives position the company for stronger results in fiscal 2027.
-
Revenue grew 11% year-over-year to $15M, with gross margin rising to 52% and adjusted EBITDA at $800K. Strategic investments in radiolabeling and data platforms are driving growth, while the company remains on track for full-year positive adjusted EBITDA.
-
Q1 revenue rebounded to $14 million, with stability year-over-year and growth in the TOS and data businesses. Gross margin declined to 43% due to higher outsourced costs, but margin expansion is expected as work shifts in-house. Management projects sequential revenue growth and a strong cash position.
Fiscal Year 2025
-
Fiscal 2025 saw record revenue, a return to profitability, and margin expansion, driven by growth in core services and new data licensing deals. The launch of radiopharmaceutical services and a strong cash position support a positive outlook, despite ongoing market headwinds.
-
Record Q3 revenue and profitability were driven by core services and the first data licensing deal, with strong gross margins and operational efficiencies. The company is expanding its data platform and expects long-term growth, though near-term volatility and industry headwinds persist.
-
Q2 delivered strong financial results with 17% revenue growth and improved margins, driven by core services and operational efficiencies. A new data licensing revenue stream is set to launch, and the funding environment is showing signs of recovery.
-
Revenue grew 12% year-over-year to $14.1 million, with improved profitability and gross margin. Operational efficiencies, reduced costs, and better revenue conversion drove a second consecutive strong quarter, though management expects some volatility ahead.
Fiscal Year 2024
-
Fiscal 2024 saw a 7% revenue decline and increased net loss due to biotech sector weakness and operational issues, but Q4 showed revenue growth and positive Adjusted EBITDA. Operational improvements and a focus on large pharma customers are expected to drive profitability and growth in fiscal 2025.